Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
June 09, 2022 08:00 ET
|
Impel Pharmaceuticals
Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa Two Additional Analyses Demonstrate...
Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
June 08, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 08:00 ET
|
Impel Pharmaceuticals
Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022 Financing...
Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 12, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
May 09, 2022 08:00 ET
|
Impel Pharmaceuticals
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation
April 25, 2022 07:00 ET
|
Impel Pharmaceuticals
SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25
April 21, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference
April 07, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 24, 2022 08:00 ET
|
Impel NeuroPharma
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021 Planned Initiation of INP105 Proof-Of-Concept Study...
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology
March 22, 2022 08:00 ET
|
Impel NeuroPharma
New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment New Analysis Considers Efficacy of Trudhesa After Variety of Acute Therapies Post Hoc Pivotal Trial Data...